In vitro study shows diphenytriazol inhibits CYP3A and CYP1A substrates in rat liver, suggesting drug interactions.
The inhibiting effect of diphenytriazol, a non-hormonal early pregnancy-terminating agent, towards cytochrome P450 (CYP) enzymes in rat liver microsomes was studied in vitro. The inhibiting effect of diphenytriazol on CYP was investigated by coincubating diphenytriazol with the specific CYP1A substrates, ethoxyresorufin and phenacetin, in microsome induced by β-naphthoflavone, with the specific CYP2B substrates, pentoxyresorufin and aminopyrine, in the microsome induced by phenobarbital, and with the specific CYP3A substrates, diazepam, testosterone, nifedipine and quinine sulfate in microsome induced by dexamethasone. The results showed that diphenytriazol inhibited the metabolism of ethoxyresorufin and phenacetin significantly, and its inhibition potential on CYP1A was higher than the typical inhibitor fluvoxamine. Diphenytriazol also inhibited the metabolism of diazepam, testosterone, nifedipine and quinine sulfate to different degrees, but its inhibition potential was relatively weaker than that of the typical inhibitor, ketoconazole. No inhibiting effect of diphenytriazol was seen on the metabolism of pentoxyresorufin and aminopyrine. The ability of diphenytriazol to inhibit rat liver CYP1A and CYP3A suggests that in human patients complex interactions may result from co-adiministration of diphenytriazol with other agents which are also substrates for CYP1A or CYP3A enzymes.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: